Indaptus Therapeutics (INDP) Competitors $3.88 -0.28 (-6.73%) Closing price 04:00 PM EasternExtended Trading$3.84 -0.04 (-1.03%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. CLRB, NXTC, ABP, DWTX, ATNF, PALI, BFRG, ATHA, BIVI, and CYCCShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Cellectar Biosciences (CLRB), NextCure (NXTC), Abpro (ABP), Dogwood Therapeutics (DWTX), 180 Life Sciences (ATNF), Palisade Bio (PALI), Bullfrog AI (BFRG), Athira Pharma (ATHA), BioVie (BIVI), and Cyclacel Pharmaceuticals (CYCC). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Its Competitors Cellectar Biosciences NextCure Abpro Dogwood Therapeutics 180 Life Sciences Palisade Bio Bullfrog AI Athira Pharma BioVie Cyclacel Pharmaceuticals Indaptus Therapeutics (NASDAQ:INDP) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Which has better earnings & valuation, INDP or CLRB? Cellectar Biosciences is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.02M-$37.66-0.10Cellectar BiosciencesN/AN/A-$44.58M-$19.91-0.25 Do insiders & institutionals believe in INDP or CLRB? 7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 20.8% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate INDP or CLRB? Indaptus Therapeutics currently has a consensus price target of $238.00, suggesting a potential upside of 6,034.02%. Cellectar Biosciences has a consensus price target of $375.00, suggesting a potential upside of 7,430.12%. Given Cellectar Biosciences' higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Indaptus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Cellectar Biosciences 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media refer more to INDP or CLRB? In the previous week, Cellectar Biosciences had 2 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 4 mentions for Cellectar Biosciences and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.95 beat Cellectar Biosciences' score of 0.12 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Indaptus Therapeutics Positive Cellectar Biosciences Neutral Is INDP or CLRB more profitable? Cellectar Biosciences' return on equity of -486.67% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -612.59% -243.78% Cellectar Biosciences N/A -486.67%-150.57% Which has more volatility and risk, INDP or CLRB? Indaptus Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. SummaryIndaptus Therapeutics and Cellectar Biosciences tied by winning 6 of the 12 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.60M$2.96B$6.11B$10.47BDividend YieldN/A57.77%5.73%4.77%P/E Ratio-0.105.0764.8323.34Price / SalesN/A763.48608.74136.45Price / CashN/A172.6337.4661.86Price / Book0.365.5112.426.81Net Income-$15.02M$33.06M$3.32B$276.80M7 Day Performance-11.42%0.95%1.01%0.27%1 Month Performance70.18%14.25%10.75%8.31%1 Year Performance-89.09%0.85%76.20%35.60% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics2.1174 of 5 stars$3.88-6.7%$238.00+6,034.0%-87.9%$4.60MN/A-0.106Gap DownCLRBCellectar Biosciences2.1338 of 5 stars$5.13-16.9%$375.00+7,209.9%-92.0%$16.38MN/A-0.2610High Trading VolumeNXTCNextCure4.4856 of 5 stars$6.07+1.2%$25.50+320.1%-60.0%$16.24MN/A-0.2490ABPAbpro3.4983 of 5 stars$0.20+2.5%$4.00+1,878.2%N/A$16.21M$180K0.0015News CoverageGap DownDWTXDogwood Therapeutics2.4194 of 5 stars$6.76+1.0%$12.00+77.5%+39.0%$15.48MN/A-0.365ATNF180 Life SciencesN/A$2.55+0.8%N/A+45.6%$15.40MN/A-0.177Gap DownPALIPalisade Bio2.1024 of 5 stars$1.68-11.8%$12.00+614.3%-45.7%$15.32M$250K-0.4110High Trading VolumeBFRGBullfrog AI0.6979 of 5 stars$1.49-0.7%N/A-44.3%$15.27M$60K-1.964Gap UpATHAAthira Pharma1.8674 of 5 stars$3.86-10.6%$4.00+3.6%-15.2%$15.22MN/A-0.2540High Trading VolumeBIVIBioVie0.4729 of 5 stars$2.01+7.5%N/A-82.5%$15.15MN/A-0.0310High Trading VolumeCYCCCyclacel Pharmaceuticals0.1349 of 5 stars$6.44-4.9%N/A-96.7%$14.43M$40K-0.0114High Trading Volume Related Companies and Tools Related Companies CLRB Alternatives NXTC Alternatives ABP Alternatives DWTX Alternatives ATNF Alternatives PALI Alternatives BFRG Alternatives ATHA Alternatives BIVI Alternatives CYCC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
